175 related articles for article (PubMed ID: 36717670)
1. Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT.
Kralj J; Pernar Kovač M; Dabelić S; Polančec DS; Wachtmeister T; Köhrer K; Brozovic A
Br J Cancer; 2023 Mar; 128(7):1344-1359. PubMed ID: 36717670
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract][Full Text] [Related]
3. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Brozovic A; Duran GE; Wang YC; Francisco EB; Sikic BI
Mol Oncol; 2015 Oct; 9(8):1678-93. PubMed ID: 26025631
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.
Pernar Kovač M; Tadić V; Kralj J; Duran GE; Stefanelli A; Stupin Polančec D; Dabelić S; Bačić N; Tomicic MT; Heffeter P; Sikic BI; Brozovic A
Cell Mol Life Sci; 2023 Sep; 80(10):294. PubMed ID: 37718345
[TBL] [Abstract][Full Text] [Related]
5. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
6. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
7. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
8. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
10. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
[TBL] [Abstract][Full Text] [Related]
11. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
12. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
[TBL] [Abstract][Full Text] [Related]
13. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract][Full Text] [Related]
14. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
15. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
16. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
[TBL] [Abstract][Full Text] [Related]
17. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Li H; Zhou Y; Cheng H; Tian J; Yang S
Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
19. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
20. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2.
du Manoir S; Delpech H; Orsetti B; Jacot W; Pirot N; Noel J; Colombo PE; Sardet C; Theillet C
J Pathol; 2022 Jul; 257(3):367-378. PubMed ID: 35302657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
